Stock Events

Stock Events

Sagimet Biosciences 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q4 2025
Next
-0.37
-0.33
-0.29
-0.25
Expected EPS
-0.314265328
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0O2.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap4.02B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, similar to Sagimet's focus on NASH (non-alcoholic steatohepatitis).
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.55B
Madrigal Pharmaceuticals focuses on the development of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, directly competing in the NASH space.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.55M
Galmed Pharmaceuticals is engaged in the development of oral therapies for the treatment of liver diseases, including NASH, positioning it as a competitor.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, with its broader portfolio, includes treatments for liver diseases such as NASH, competing with Sagimet's focus areas.
Agios Pharmaceuticals
AGIO
Mkt Cap2.06B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including metabolic disorders, which puts it in competition with Sagimet's metabolic disease focus.

About

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Show more...
CEO
Mr. David A. Happel
Employees
16
Country
Germany
ISIN
US7867001049

Listings

MU
DE
0O2.MU
STU
DE
0O2.STU
F
DE
0O2.F
XNAS
US
SGMT

0 Comments

Share your thoughts

FAQ

What is Sagimet Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sagimet Biosciences stocks are traded under the ticker 0O2.MU.
When is the next Sagimet Biosciences earnings date?▼
Sagimet Biosciences is going to release the next earnings report on May 20, 2026.
What were Sagimet Biosciences earnings last quarter?▼
0O2.MU earnings for the last quarter are -0.25 EUR per share, whereas the estimation was -0.37 EUR resulting in a +32.9% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Sagimet Biosciences have?▼
As of April 12, 2026, the company has 16 employees.
In which sector is Sagimet Biosciences located?▼
Sagimet Biosciences operates in the Other sector.
When did Sagimet Biosciences complete a stock split?▼
Sagimet Biosciences has not had any recent stock splits.
Where is Sagimet Biosciences headquartered?▼
Sagimet Biosciences is headquartered in San Mateo, Germany.